Trials / Unknown
UnknownNCT04624971
A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.
Conditions
Timeline
- Start date
- 2020-11-01
- Primary completion
- 2020-11-01
- Completion
- 2020-11-01
- First posted
- 2020-11-12
- Last updated
- 2020-11-12
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04624971. Inclusion in this directory is not an endorsement.